Patient has never received cumulative cardio-toxic therapy (anthracycline, mitoxantrone,...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-OBLIGATE-CARDIO-TOXIC-NAIVE |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-DLBCL-2024 SRC-NCCN-BCELL-2025 |
Red Flag Origin
| Definition | Patient has never received cumulative cardio-toxic therapy (anthracycline, mitoxantrone, trastuzumab, mediastinal/cardiac radiation). Cumulative anthracycline exposure budget remains intact; full standard regimens (R-CHOP, AC-T, ABVD, BEACOPP) are dose-feasible without dose-cap concern. Distinct from RF-ORGAN-CARDIAC-LVEF-LOW (which gates on functional reserve regardless of prior exposure). |
|---|---|
| Clinical direction | intensify |
| Category | prior-therapy-class |
Trigger Logic
{
"all_of": [
{
"finding": "prior_anthracycline_received",
"value": false
},
{
"finding": "prior_trastuzumab_received",
"value": false
},
{
"finding": "prior_mediastinal_rt",
"value": false
}
],
"type": "composite_score"
}
Notes
Cumulative anthracycline cardiotoxicity is dose-dependent: doxorubicin ≥250 mg/m² lifetime — significant CHF risk, ≥450 mg/m² — high risk (Swain 2003); epirubicin equivalent ≈ 0.7x doxorubicin; idarubicin ≈ 4x doxorubicin per mg. Standard R-CHOP delivers 300 mg/m² across 6 cycles — leaves headroom for relapse/salvage. Patients who received AC-T (240 mg/m² doxorubicin) for breast then progress to lymphoma have ~60 mg/m² remaining safely; substitute liposomal doxorubicin or R-CEOP. Trastuzumab cardiotoxicity is reversible (unlike anthracycline) but co-administration with anthracycline contraindicated; staggered AC→T → trastuzumab standard. Mediastinal RT (Hodgkin survivor) doubles anthracycline cardiotoxicity risk per equivalent dose.
Used By
Red flag
RF-ORGAN-CARDIAC-LVEF-LOW- Reduced left ventricular ejection fraction (LVEF <50% by echocardiogram or MUGA). Anthrac...